

**Amendment to the Claims**

Claims 1-7 (Canceled)

8. (Currently amended) A transgenic mouse whose genome comprises ~~comprising a null a~~  
disruption in the cerberus (Cer1) gene, said disruption comprising replacement of nucleotides  
corresponding to bases 241 through 528 of SEQ ID NO:1 with a Neo cassette-allele.

Claims 9-16 (Canceled)

17. (Currently amended) The transgenic mouse of claim ~~28~~48, wherein the transgenic mouse  
exhibits anti-depressive behavior ~~decreased susceptibility to depression and/or hypoactivity~~  
~~relative to a wild-type control mouse.~~
18. (Currently amended) The transgenic mouse of claim 8, wherein ~~the transgenic~~said mouse is  
homozygous for ~~the null allele~~said disruption.

Claims 19-25 (Canceled)

26. (New) The transgenic mouse of claim 18, wherein said mouse exhibits in the open field test,  
decreased average velocity and decreased total distance traveled, relative to a wild-type  
control mouse.
27. (New) The transgenic mouse of claim 26, wherein said mouse exhibits hypoactivity.
28. (New) The transgenic mouse of claim 18, wherein said mouse exhibits in the tail suspension  
test, decreased total time spent immobile, relative to a wild-type control mouse.
29. (New) The transgenic mouse of claim 18 wherein said mouse exhibits in the open field test,  
increase in the number of fecal boli, relative to a wild-type control mouse.
30. (New) The transgenic mouse of claim 29 wherein said mouse exhibits increased fear,  
anxiety or nervousness.